Stay updated with breaking news from Mark Lappe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Inhibrx pickup gives Sanofi access to INBRX-101, a human recombinant protein that is being investigated in patients with a rare disease known as alpha-1 antitrypsin deficiency.
Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...
Shares of Inhibrx, Inc. (NASDAQ:INBX – Get Rating) were up 5.6% on Friday . The stock traded as high as $20.77 and last traded at $20.73. Approximately 61,727 shares were traded during trading, a decline of 84% from the average daily volume of 396,952 shares. The stock had previously closed at $19.63. Wall Street Analysts […]
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) fell 7.4% on Monday . The company traded as low as $15.83 and last traded at $15.88. 54,717 shares were traded during mid-day trading, a decline of 86% from the average session volume of 400,795 shares. The stock had previously closed at $17.15. Wall Street Analysts Forecast Growth A […]